| Alchem can be a **value-creating partner** for both established and start-up [[:pharmaceutical companies]] by providing qualified infrastructure and trained personnel for all stages of drug development including design and synthesis of [[:novel compounds]], synthesis of analogs of lead compounds, process development and optimization, analytical method development and validation, stability studies for drugs and intermediates, cGMP manufacturing of APIs and products for clinical studies, and documentation for all stages of drug development. | Alchem can be a **value-creating partner** for both established and start-up [[:pharmaceutical companies]] by providing qualified infrastructure and trained personnel for all stages of drug development including design and synthesis of [[:novel compounds]], synthesis of analogs of lead compounds, process development and optimization, analytical method development and validation, stability studies for drugs and intermediates, cGMP manufacturing of APIs and products for clinical studies, and documentation for all stages of drug development. |
| Our partners and collaborators include the [[:National Cancer Institute]] (NCI), part of the [:National Institutes of Health]] (NIH), the [[:National Institute of Standards and Technology]] (NIST), the U.S. Army Medical Research Acquisition Activity (USAMRAA), the U.S. [[:Department of Agriculture]] (USDA), the Dr. Margarete Fischer-Bosch- [[:Institute of Clinical Pharmacology]] (ICP), [[:Gemphire Therapeutics]], Inc. (NASDAQ: GEMP), [[:Cerenis Therapeutics Holding SA (CEREN.PA), [[:Brickell Biotech]], Inc., [[:FLUCEL LLC]], [[:Nanopharmaceutics]], [[:MRIGlobal]], [[:Pace Analytical Labs]], [[:Southern Research]], and the [[:University of Florida]] [[:UF|INNOVATE]] - [[:Sid Martin Biotech]] ((https://web.archive.org/web/20180705030629/http://www.alchem.com/news)) | Our partners and collaborators include the [[:National Cancer Institute]] (NCI), part of the [[:National Institutes of Health]] (NIH), the [[:National Institute of Standards and Technology]] (NIST), the U.S. Army Medical Research Acquisition Activity (USAMRAA), the U.S. [[:Department of Agriculture]] (USDA), the Dr. Margarete Fischer-Bosch- [[:Institute of Clinical Pharmacology]] (ICP), [[:Gemphire Therapeutics]], Inc. (NASDAQ: GEMP), [[:Cerenis Therapeutics Holding SA (CEREN.PA), [[:Brickell Biotech]], Inc., [[:FLUCEL LLC]], [[:Nanopharmaceutics]], [[:MRIGlobal]], [[:Pace Analytical Labs]], [[:Southern Research]], and the [[:University of Florida]] [[:UF|INNOVATE]] - [[:Sid Martin Biotech]] ((https://web.archive.org/web/20180705030629/http://www.alchem.com/news)) |
